Thanks to a combination of favorable policies, rising demand quality, upgraded manufacturing capabilities, technological innovation, and capital investment, the medical device industry has become the fastest-growing sector within the healthcare industry—and also one of the most promising investment hotspots in the capital market. According to forecasts by the China Pharmaceutical Industry Information Center, China’s medical device market size will exceed 600 billion yuan in 2019, with an expected annual compound growth rate of 16.8%. In the future medical device market, innovation will be the primary driver of its rapid growth and also the fundamental solution for promoting supply-side structural reform. China’s medical device innovation has now entered its golden decade.

　　1. How investment institutions can seize the opportunities presented by the golden decade

　　For investment firms, navigating the highly diverse medical device industry and fully seizing the golden decade of innovation presents a rather tricky challenge—especially for those just starting to enter the medical device sector. On the surface, there seem to be countless investment opportunities, yet they’re scattered and fragmented. While the overall market space may not appear particularly large, some seemingly unremarkable segments have seen remarkably strong growth among certain companies. So, amid this vast array of categories, how can investors effectively identify and capitalize on the right opportunities?

　　There’s no shortcut to solving this issue; we can only examine it from three perspectives: First, the size and sustained growth potential of the specific sub-industry in which the project is situated; second, the innovativeness of the project’s core products, their disruptive potential in clinical applications, and the leading market opportunities they present; third, the founder and management team. The first two aspects can be clearly understood and determined only through systematic industry research. We’ve divided medical devices into seven sub-sectors: in vitro diagnostics, imaging, cardiovascular and cerebrovascular, surgical/orthopedic, oncology, medical artificial intelligence, and other comprehensive categories. We’ve conducted thorough, systematic industry research on each of these sub-sectors, meticulously mapping out nearly all significant companies within each one. We continuously track and update the progress of these companies, ensuring timely follow-up on investment opportunities. The advantage of doing so is that we gain a comprehensive and deep understanding of developments within each sub-sector, systematically monitor top-performing companies, and thus approach the first two aspects with confidence and precision.